Dear all,
We are pleased to announce that one of the 5 finalists of the 2014 Innovation Prize has entered into a $25 million development agreement with pharmaceutical company Pfizer.
In fact, Belgian company iTeos Therapeutics, led by Michel Detheux, is developing drug candidates that target Indoleamine-2,3-Dioxygenase (IDO1) and Tryptophan-2,3-Dioxygenase (TDO2).
This news highlights the quality of the various projects submitted during the Innovation Award and also the high level of expertise of the various members of the Jury.
The 7th edition of the Innovation Award will start on February 2nd, do not hesitate to ask for more information about the next edition.
Rafi Mardachti, Chairman and CEO
